Device Trial Radar · NCT02472106
Impact of Postdilatation With the InterValve V8 Aortic Valvuloplasty Balloon Following TAVI Procedure
Last checked: Nov 19, 2026Latest source record: Aug 31, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Jun 2015
Primary completion
Aug 2016
Study completion Aug 2016
Sponsor
- Lead sponsor
- InterValve, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 15, 2015
Design
- Study type
- Observational
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to monitor the safety and performance of the V8 balloon when used as a postdilatation balloon in self-expanding Transcatheter Aortic Valve Implantation (TAVI) device procedures. The study product is CE marked for balloon aortic valvuloplasty (BAV), and is being investigated for an expanded intended use.
Conditions
- Aortic Valve Stenosis
Interventions
Post-dilatationDevice
Post-dilatation in self-expanding TAVI device procedures
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy Endpoint: V8 Device PerformanceTime frame: Intra-Procedure
- Safety Endpoint: Serious Adverse Events (SAE)Time frame: Intra-procedure until discharge or 7 days post-procedure, whichever comes first. (Typical discharge is expected to be within 7 days.)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.